Prudential Upgrades CuraGen Rating to Buy
CuraGen Corp. (CRGN ) shares were sharply higher after the genomics research firm announced that it had entered into two alliances with pharmaceuticals giant Bayer. Prudential Securities upgraded its investment recommendation on the shares to strong buy from accumulate.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- Bitcoin Futures Deliver Wild Ride as Debut Brings Rally, Halts
- Investors Told to Brace for Steepest Rate Hikes Since 2006
- A Manager of $42 Billion Fears Bubble in World's Biggest Stocks
- Longtime NPR Host Tom Ashbrook Is Facing Misconduct Allegations
- Buffett's About to Get $3 Billion Back From Burger King Owner